About
Novan, Inc. is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs.
Novan has a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams, promoting products for plaque psoriasis, rosacea and acne. The U.S. Food and Drug Administration (“FDA”) has accepted Novan’s new drug application (“NDA”) submission for review for berdazimer gel, 10.3% (SB206) as a topical prescription gel for the treatment of molluscum contagiosum. The Company also has a pipeline of potential product candidates using its proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.
NOVAN PRIDE UNDERPINS OUR EFFORTS
Performance
We are empowered to take ownership while being accountable in providing timely and compliant deliverables
Respectful
We are collaborative and foster open dialogue to create trust while assuming positive intent
Innovative
We are responsive to our science, our customers, our patients, and we are open to new perspectives and ideas in all that we do
Dynamic
We are transparent in communicating change, and we are laser-focused on patients’ needs, and the well-being of our employees and our business
Engaged
We are committed and dedicated to working together as a team to improve patients’ lives and celebrate our successes along the way
Novan, Inc. is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. We are developing berdazimer gel, 10.3% (SB206) as a topical prescription gel for the treatment of viral skin infections, with current emphasis on molluscum contagiosum.
Novan completed the acquisition of EPI Health in early 2022. EPI Health equips the company with a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams. Following the acquisition, the company promotes products for plaque psoriasis, rosacea and acne. Novan also has a pipeline of potential product candidates using our proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.
NOVAN PRIDE UNDERPINS OUR EFFORTS
Performance
We are empowered to take ownership and provide quality outcomes and timely deliverables
Respectful
We are collaborative, we participate in active listening and support an open dialogue
Innovative
We are responsive to our science, and are open to new perspectives and ideas in all that we do
Dynamic
We are intentional in managing change, and we are responsive to our business, employees, and patient needs
Engaged
We are committed and dedicated to working together to improve patients’ lives